A double‑blind, randomized phase 2a trial in adults with obesity and metabolic syndrome found that monlunabant produced clinically meaningful weight loss alongside improvements in waist circumference, triglycerides, and blood pressure compared with placebo. The safety profile was acceptable over the treatment period, with mainly mild gastrointestinal events. These data position monlunabant as a promising candidate for cardiometabolic risk modification in high‑burden obesity phenotypes. To read more Click Here ##Reference## Knop, Filip K et al.
Efficacy and safety of monlunabant in adults with obesity and metabolic syndrome: a double-blind, randomised, placebo-controlled, phase 2a trial. The Lancet Diabetes & Endocrinology, Volume 13, Issue 11, 911 - 923.## In your experience, which factor most influences adoption of new anti‑obesity agents in high‑risk metabolic syndrome? a) Magnitude…
